Introduction {#sec1-1}
============

Venous thromboembolism (VTE) comprising of deep vein thrombosis (DVT) and pulmonary embolism (PE) can result in significant mortality, morbidity, and healthcare expenditure.\[[@ref1]\] Approximately, one-third of patients with symptomatic VTE manifests PE, whereas two-thirds manifest DVT alone.\[[@ref2]\] Both DVT and PE can be clinically silent (asymptomatic) and hence not suspected. If undiagnosed, asymptomatic VTE can lead to chronic venous disease or recurrent VTE and long-term debilitating sequelae such as postthrombotic syndrome and chronic thromboembolic pulmonary hypertension.\[[@ref3][@ref4]\] VTE is not only disabling but also prolongs hospital stay and increases the cost of treatment. Along with myocardial infarction and arrhythmia (due to electrolyte imbalance), PE is one of the commonest causes of sudden unexplained deaths in hospitalized patients.\[[@ref5]\]

It is estimated that 20 million cases of lower extremity DVT occur in the USA alone.\[[@ref6]\] Routine postoperative venography has shown an incidence of 60% in patients undergoing orthopedic surgery.\[[@ref7]\] The prevailing notion that the incidence of VTE in Asians is less than that in the Western population has been disproved by recent studies.\[[@ref8][@ref9]\] The incidence of postoperative DVT in Indian patients undergoing major lower limb surgery is as high (43.2% and 60% patients in the groups with and without prophylaxis, respectively) as seen in the Western world.\[[@ref10]\]

Given the growing burden of VTE in India and lack of substantial Indian data on characteristics of VTE patients, use of diagnostics tools, prophylaxis, treatment options, and clinical outcomes in VTE, there was a need to systematically collect such data.

The aim of this registry was to collect "real world" data on patient characteristics, clinical outcomes, predictors of mortality in acute DVT, management strategies and temporal trends in VTE. The intent was to collect and provide data that would reflect actual day-to-day clinical practice, rather than results of highly controlled clinical trials with restricted study populations and imposed experimental intervention.

Subjects and Methods {#sec1-2}
====================

Institutional Ethics Committee approval was obtained before initiation of data collection. Consecutive medical records of inpatients and outpatients between January 2006 and December 2010, meeting eligibility criteria (confirmed diagnosis of acute or acute-on-chronic DVT by Doppler ultrasound scan and/or PE by chest computed tomography scan, pulmonary angiography or V/Q scan) were identified and collected from the general medical records and/or radiology departments at each of the three participating hospitals. Hospital data were used to obtain the total number of patients who were annually registered at the hospital from 2006 to 2010.

The collected information was verified against source documents. Data were managed with validated software "Oracle Clinical" (version 4.6, Oracle Health Sciences). Data were processed and analyzed using SAS (version 9.1, statistical analysis system). For the purpose of analysis, "acute-on-chronic" DVT was considered as "acute" DVT. Descriptive statistics were used to present patient characteristics, management strategies, and clinical outcomes of patients. Annual incidence rates (95% CI) of VTE per 100,000 hospital registrations over a period of 5 years were reported for each site.

Fisher\'s exact test was used to determine differences in the incidence of acute DVT (±PE) over the years 2006--2010. Cochran--Armitage trend test was used to examine the direction (positive or negative) of the trend.

As primary analyses were purely descriptive, no formal sample size calculations were done.

Results {#sec1-3}
=======

A total of 949 medical records were reviewed. Information from 59% (556/949) records was captured for the registry. The remaining 41% (393/949) medical records were not included because they did not satisfy the inclusion criteria. Data from 99% (549/556) of the included records were analyzed. Data from seven patients were excluded as there was no radiologically confirmed diagnosis of PE.

A total of 64% (352/549) patients had acute DVT without PE, 23% (124/549) had acute DVT with PE, and 13% (73/549) had PE. Eighty-seven percent (476/549) of patients had acute DVT (±PE), and 36% (197/549) had PE (± acute DVT) \[[Figure 1](#F1){ref-type="fig"}\].

![Overall distribution of venous thromboembolism patients (*n* = 549)](IJCCM-20-150-g001){#F1}

A total of 21% (115/549) of patients visited the hospitals directly without being referred by a physician. The proportion of patients referred from different medical specialties is mentioned in [Table 1](#T1){ref-type="table"}.
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Venous thromboembolism patients referred from different medical specialties (*n*=434)
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Demographics and characteristics of venous thromboembolism patients {#sec2-1}
-------------------------------------------------------------------

The demographic characteristics of the VTE patients are mentioned in [Table 2](#T2){ref-type="table"}.

###### 

Demographic characteristics of venous thromboembolism patients (*n*=549)
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### Risk factors for venous thromboembolism patients {#sec3-1}

A total of 182 patients had evidence of one risk factor, 126 had evidence of two risk factors, 70 had evidence of three risk factors and 31 had four or more risk factors recorded. Patients undergoing orthopedic surgery constituted 22% (33/152) of all surgical patients \[[Table 3](#T3){ref-type="table"}\].
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Risk factors for venous thromboembolism
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### Co-morbidities in venous thromboembolism patients {#sec3-2}

Based on a review of the available records, 157 patients had a single co-morbidity, 81 had two co-morbidities, 23 had three co-morbidities, and 16 had four or more co-morbidities. About 21% (114/549) of patients were "acutely medically ill" (myocardial infarction, heart failure, chronic obstructive pulmonary disease, ventilator dependency, sepsis, or pneumonia) \[[Table 4](#T4){ref-type="table"}\].
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Co-morbidities in venous thromboembolism patients
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### Clinical presentation of venous thromboembolism {#sec3-3}

Of the 476 patients with DVT, 2% (9) had upper extremity DVT, 97% (462) had lower extremity DVT and the site of DVT was not known in 5 patients. A total of 31% (143/462) patients had DVT in the right limb, 54% (249/462) in the left limb and 9% (41/462) in both limbs (site not known in 29 patients). Of the 462 patients with lower extremity DVT, 61% had proximal DVT, 13% had distal DVT, and 7% had proximal and distal DVT. A total of 39% (215/549) patients were diagnosed with VTE during their hospital stay, 54% (296/549) were admitted to hospital with a diagnosis of VTE, and 7% (38/549) were diagnosed and continued to be managed in the outpatient department \[[Figure 2](#F2){ref-type="fig"}\]. The duration of hospitalization after diagnosis of VTE is shown in [Table 5](#T5){ref-type="table"}.

![Place of detection of venous thromboembolism (*n* = 549)](IJCCM-20-150-g006){#F2}

###### 

Duration of hospitalization after diagnosis of venous thromboembolism
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A smaller proportion of patients (15%; 81/549) was diagnosed with VTE during the postoperative period. [Figure 3](#F3){ref-type="fig"} shows the proportion of patients with VTE at different time points during the postoperative period. Of those diagnosed beyond 6 weeks, 21% (3/14) had orthopedic surgery (hip fracture surgery).

![Diagnosis of venous thromboembolism during the postoperative period (*n* = 81)](IJCCM-20-150-g008){#F3}

The most common (73%) symptom was "swelling of the limb" among patients with VTE \[[Table 6](#T6){ref-type="table"}\].

###### 

Symptoms in venous thromboembolism patients
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Management strategies for venous thromboembolism patients {#sec2-2}
---------------------------------------------------------

### Diagnostic tools for venous thromboembolism {#sec3-4}

In merely 4% of all the patients, DVT was also confirmed by venography. PE was confirmed by pulmonary angiography in 27% of all the patients \[[Table 7](#T7){ref-type="table"}\].
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Diagnostic tools
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### Anticoagulant treatment in venous thromboembolism {#sec3-5}

A total of 94% (515/549) of patients were recommended anticoagulants. Heparin (low molecular weight heparin \[LMWH\]/unfractionated heparin \[UFH\]) alone, a combination of heparin (LMWH/UFH) and oral anticoagulant (warfarin), and fondaparinux sodium alone were recommended to 82% (420/515), 13% (66/515), and 2% (12/515) patients, respectively as initial anticoagulation. The rest of patients were recommended streptokinase, urokinase, or tissue plasminogen activator.

Five percent (25/515) of patients were recommended LMWH alone, and 76% (393/515) were recommended either warfarin or acenocoumarol alone for long-term anticoagulation.

The median duration of initial anticoagulation was 5 days while that of long-term anticoagulation was 180 days (6 months).

Anticoagulants were needed to be stopped because of bleeding in only 2% (9/515) patients.

Clinical outcomes in VTE patients are mentioned in Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}.
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Clinical outcomes in patients diagnosed with venous thromboembolism during hospital stay
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###### 

Clinical outcomes in patients admitted to hospital with a diagnosis of venous thromboembolism
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### Annual incidence of acute deep venous thrombosis including the trend over a period of 5 years {#sec3-6}

The annual incidence of acute DVT (±PE) increased from 2006 to 2010 at all the three sites \[[Figure 4](#F4){ref-type="fig"}\]. However, a formal site-wise statistical analysis could not be performed to analyse trends in the incidence rates in acute DVT (±PE) and PE alone as there were zero observations in some instances.

![Incidence of acute deep vein thrombosis (with or without pulmonary embolism) over a 5 years period (2006--2010) at three sites](IJCCM-20-150-g013){#F4}

Discussion {#sec1-4}
==========

To our knowledge, this is the first multicenter, retrospective registry in India involving patients with VTE that reflect real-world clinical practice.

In contrast with the Western data in which VTE is predominantly a disease of older age,\[[@ref11]\] 44% patients in our study were between 40 and 59 years of age while 34% were below 40 years, particularly those with PE. In a study from North India, 80% of PE patients were below 50 years.\[[@ref12]\] Men constituted 70% of our registry, more than those reported from Vellore registry (48%),\[[@ref13]\] but similar to those reported in the ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for VTE in the Acute Hospital Care Setting) study (69%).\[[@ref14]\] One of the reasons for this could be significantly high levels of homocysteine (thrombophilia marker) in males as compared to females as reported in an Indian study.\[[@ref15]\] Fewer Indian women use oral contraceptives and postmenopausal hormone replacement therapy, which are known to be risk factors for thrombosis. This is supported by the fact that only 1% of women in this registry reported the use of oral contraceptives, and none reported use of hormonal replacement therapy.

A total of 28% of the overall referrals were from cardiologists. The majority (82%) of the referrals were from medical rather than surgical (15%) specialties as against a referral rate of 93% from surgeons at Vellore.\[[@ref13]\] Our finding complements that from the ENDORSE study\[[@ref14]\] in which 55% of the medical patients at risk of VTE had cardiovascular disease. Majority (53%) of patients in our study had co-morbid cardiovascular disease including diabetes mellitus; it is possible that these patients visited a cardiologist for their cardiovascular ailment (s) and were then referred by the cardiologist to vascular disease specialist (investigator). DVT without PE was mostly referred by family/general physicians. Most (89%) of these patients had swelling of the (lower) limb. It is possible that these patients may not have felt the need to visit a specialist for a symptom like "swelling of limb," instead visited their family physician. It is very encouraging to know that family physicians suspected DVT in these situations and referred the patient to a specialist.

Patients with a history of VTE are about 8 times more likely to develop a new episode during a subsequent high-risk period compared with patients without a history of DVT or PE.\[[@ref16]\] Prior history of DVT was the most (34%) common risk factor in patients who had only DVT, whereas past history of PE, trauma, and immobilization for more than 3 days were the most common risk factors in patients who had only PE. Patients undergoing orthopedic surgery constituted 22% (33/152) of all surgical patients. Six percent patients received blood transfusion while 5% patients had obstetrics/gynecological surgeries. Our results (major lower limb surgery as a risk factor in 3% patients) appear to be consistent with those reported in the ENDORSE study, which reported DVT in 4.4% patients undergoing major lower limb surgery.\[[@ref14]\] Other studies from India have reported a DVT incidence rate ranging from 8% to 20% in major lower limb surgery.\[[@ref17][@ref18]\] Malignancy has been reported as a risk factor in 31% patients.\[[@ref13]\] However, in our study, only 7% of patients had malignancy as a predisposing factor. Among the malignancies, genitourinary cancer had the highest incidence (45%).

Hypertension (25%) was the most common co-morbidity followed by diabetes mellitus (19%) in this patient population. In addition, obesity (11%) was a common risk factor in DVT complicated by PE. Our findings support an Asian (Korean) study that demonstrated prevalence of the metabolic syndrome in 48% patients with VTE.\[[@ref19]\] Co-morbid neurological disease (other than stroke) and ventilator dependency were also commonly found in patients with DVT (10%) and PE (11%) respectively. Both these conditions immobilize patients for prolonged periods of time, predisposing them to VTE. About 21% of patients were acutely medically ill.

Venography and pulmonary angiography are the gold standard for diagnosis of DVT and PE respectively.\[[@ref20]\] In our study, venography was used in just 4% patients and pulmonary angiography in less than one-third of the patients. Perhaps the relatively high cost of these tests and limited availability of such procedures may be the limiting factors. Doppler ultrasonography still remains the widespread diagnostic modality for detecting VTE in India.

Overall, most (93%) patients were managed as inpatients (39% diagnosed with VTE during hospital stay and 54% admitted to hospital with a diagnosis of VTE). PE was mostly (75%) diagnosed during hospital stay. A mean duration of hospitalization of 7--9 days after diagnosis of VTE is supported by published data.\[[@ref21]\] In selected low-risk patients, outpatient treatment of DVT and PE may be considered.\[[@ref22][@ref23][@ref24]\] This approach was observed in a small proportion (7%) of patients who were managed on an outpatient basis, nearly all (97%) of whom had only DVT.

The reported prevalence of postsurgical VTE in our study (15%) was half of that (30%) reported in Vellore registry.\[[@ref13]\] This could be explained by higher referral rate from surgeons at Vellore compared to that of our sites. Most (40%; 32/81) DVT cases were diagnosed between 2 and 6 postoperative weeks, but PE in most cases (70%; 7/10) was diagnosed during the first postoperative week. We notice that acute DVT complicated by PE was less (6%; 7/124) frequently diagnosed during the postoperative period as against 18% (64/352) and 14% (10/73) of acute DVT alone and PE alone, respectively.

Anticoagulants are the mainstay of treatment for VTE. The use and duration of anticoagulants in our registry appears to be consistent with the American College of Chest Physicians treatment guidelines,\[[@ref25]\] which recommend at least 5 days of initial anticoagulation with parenteral anticoagulation (LMWH, fondaparinux, intravenous UFH, or subcutaneous UFH) and at least 3 months of long-term anticoagulation treatment with Vitamin K antagonist.

Bleeding is the most serious complication of anticoagulation treatment and is a major concern for clinicians particularly as the patient\'s age advances. In this registry, anticoagulant treatment was needed to be stopped because of bleeding in only 2% of the study population. The prospective REITE registry has reported a rate of 3% for major/fatal bleeds.\[[@ref26]\] Thus, the fear of bleeding complications, which decreases the use of anticoagulant treatment, appears to be minimal.

Almost all (97%) hospitalized patients were discharged from hospital. DVT complicated by PE (60%) and PE alone (75%) were more frequently shifted to Intensive Care Unit than those who had DVT alone (25%). Similar to published data in which hospital readmission rate for VTE was 5% for primary and 14% for secondary diagnosis,\[[@ref27]\] we report a hospital readmission rate of 6%; however we do not know the cause for readmission.

Overall 4% of hospitalized patients died. The death rate was 7% among those diagnosed with VTE during hospital stay as against a rate of 1% among those who were hospitalized with a diagnosis of VTE. Over 90% of patients treated on an outpatient basis obtained symptomatic relief with treatment. In our study, the hospital discharge rate (97%) was more than triple and death rate was a quarter of that reported by Pandey *et al*.\[[@ref28]\] (hospital discharge rate 31% and death rate 16%) at a university hospital in Delhi.

Our data show a significant increase in acute DVT (±PE) from 2006 to 2010. This can be explained by the increased awareness of VTE in India as well as the advent of better diagnostic modalities, such as duplex ultrasonography becoming more readily available and accepted. Although there was no significant change in the number of PE cases from 2006 to 2010, the burden of PE is almost double (13% of all VTE) of 7%, rate reported at Christian Medical College, Vellore during a 10-year period from 1996 to 2005.\[[@ref13]\] Our finding is consistent with a study from North India that reported a 16% incidence of PE in adult medical autopsies.\[[@ref12]\]

This study has the expected limitations of any retrospective review including the availability of complete records for all patients, although a robust review of the data on medical charts was conducted. Controlling for bias and confounders is difficult as there is no randomization and no blinding. Follow-up data of patients after hospital discharge were not available. In cases of death, the exact cause of death was not mentioned on medical records. Further, the clinic charts reviewed in this study included a mix of those from Vascular Surgery and Hematology Departments, limiting the generalizability of the study results. Despite these limitations, this study provides large amount of useful information in a short span of time on patient characteristics, clinical outcomes, management strategies, and temporal trends in VTE, based on "real world" data that reflect actual day-to-day clinical practice over a period of 5 years across three sites in India. We believe that this information will serve as a guide in the optimal implementation of VTE prophylaxis and treatment, to improve patient outcomes and to decrease the occurrence of VTE in India.

Conclusion {#sec1-5}
==========

Real world data reflecting actual day-to-day clinical practice in VTE over a period of 5 years across three sites in India showed that VTE is not uncommon in Indian patients and that acute DVT was responsible for the substantial burden of VTE. Bleeding was not the limiting factor for anticoagulant treatment in most patients. We believe that this information will serve as a guide in the optimal implementation of VTE prophylaxis and treatment, to improve patient outcomes and to decrease the occurrence of VTE in India.
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